Jain PharmaBiotech (Switzerland)

The fields where it stands highest, over all time, ranked among every institution above the floor in each field.

Each strip is that field’s whole ranked pool, with the notch where Jain PharmaBiotech (Switzerland) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).

Where its research is concentrated relative to its size: Molecular Biology takes 6.0× the share of its output that it takes of world research.

1. Molecular BiologySubfield · 86.4 works6.0×

Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

• Immunology and Microbiology 8.3×
• Chemistry 5.3×
• Medicine 3.9×
• Health Professions 3.2×

Ranked on the composite score, Kewal K. Jain lead among researchers whose main affiliation is Jain PharmaBiotech (Switzerland).

1. 1 🇨🇭 Kewal K. Jain Switzerland · #1,012,838 worldwide 81 citations · 83 works

By fractional works in all years, weighted toward what it does more of than the world: Oxidative Stress, Nanoparticles, Pharmacokinetics, Neurological Disorders, Bioinformatics, Cancer Therapy, Biosensors and Synaptic Plasticity.

By volume in 2022–2025: Vasculitis and related conditions, Renal Diseases and Glomerulopathies, Sarcoidosis and Beryllium Toxicity Research and Antimicrobial agents and applications.

1. 1 Vasculitis and related conditions Pulmonary and Respiratory Medicine 0 works
2. 2 Renal Diseases and Glomerulopathies Nephrology 0 works
3. 3 Sarcoidosis and Beryllium Toxicity Research Physiology 0 works
4. 4 Antimicrobial agents and applications Organic Chemistry 0 works
5. 5 Safe Handling of Antineoplastic Drugs Occupational Therapy 0 works
6. 6 Medical Device Sterilization and Disinfection Microbiology 0 works

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

Output in 2018–2022 was 77% higher than in 2013–2017.

• University of Basel
• Novartis (Switzerland)
• University Hospital of Basel
• Roche (Switzerland)
• Swiss Tropical and Public Health Institute
• Multidisciplinary Digital Publishing Institute (Switzerland)
• University Children’s Hospital Basel
• Bank for International Settlements